The Role of Glutathione Supplementation in Type 2 Diabete

The paper, "Randomized Clinical Trial of Long-Term Glutathione Supplementation for Protection from Oxidative Damage and Improved Glycemic Control in Elderly Type 2 Diabetic Patients" investigates the effects of oral glutathione (GSH) supplementation on oxidative stress and glycemic control in individuals with Type 2 Diabetes Mellitus (T2DM).

 This randomized clinical trial focuses on the potential benefits of GSH in alleviating oxidative stress, a major factor in the progression of diabetes and its complications, while also examining improvements in glycemic markers. Below is a detailed discussion of the key findings of the clinical trial.

Study Design

Participants and Groups

• Sample Size: The study enrolled 250 diabetic patients and 104 non-diabetic controls for comparison.
• Intervention Group (DG): 125 diabetic patients received 500 mg of oral GSH daily in addition to their standard anti-diabetic therapy.
• Control Group (D): 125 diabetic patients continued standard anti-diabetic therapy without GSH supplementation.
• The study spanned six months, with assessments at baseline, 3 months, and 6 months.

Outcome Measures

The primary outcomes included:

• Oxidative Stress Markers:
• Reduced Glutathione (GSH) levels.
• Oxidized Glutathione (GSSG) levels.
• 8-hydroxy-2'-deoxyguanosine (8-OHdG), a marker for oxidative DNA damage.
• Glycemic Markers:
• Glycated hemoglobin (HbA1c).
• Fasting plasma glucose (FPG).
• Postprandial glucose (PPG).
• Fasting Plasma Insulin (FPI).

Key Findings

1. Reduction in Oxidative Stress

• Improvement in GSH Levels:
• The intervention group (DG) showed a significant increase in GSH levels, rising from a baseline median of ~440 µM to ~1000 µM after six months (Cohen's d = 1.01, p < 0.001).
• In the control group (D), the changes were minimal and not statistically significant, with levels increasing from ~400 µM to ~420 µM (p = 0.22).
• Decrease in Oxidative Damage (8-OHdG):
• The 8-OHdG marker significantly declined in the GSH-supplemented group, from a baseline of 481 ng/µg DNA to ~300 ng/µg DNA over six months (Cohen's d = -1.07, p < 0.001).
• The control group showed negligible changes in 8-OHdG levels (p = 0.48).
• Ratio of GSH/GSSG:
• A higher GSH/GSSG ratio was observed in the intervention group (DG) at the end of the study, reflecting reduced oxidative stress.

2. Improvement in Glycemic Control

HbA1c Reduction:

• Participants in the GSH group demonstrated a significant reduction in HbA1c levels, dropping from 8.0% ± 1.0% to 7.4% ± 0.8% by the end of the trial (Cohen's d = -0.41, p < 0.05).
• The control group exhibited only a slight reduction, from 8.1% ± 1.0% to 8.0% ± 0.8%, which was not statistically significant (p = 0.32).
• Fasting Plasma Glucose (FPG):
• FPG levels in the GSH group decreased slightly, from 140 ± 15 mg/dL at baseline to 132 ± 12 mg/dL at six months.
• In the control group, FPG levels remained stable, from 140 ± 14 mg/dL at baseline to 138 ± 13 mg/dL (p = 0.52).
• Postprandial Glucose (PPG):
• The GSH group exhibited a statistically significant reduction in PPG levels, from 210 ± 20 mg/dL to 190 ± 18 mg/dL by six months (Cohen's d = -0.55, p < 0.001).
• PPG levels in the control group showed no significant change (p = 0.38).

Book your glutathione from evercare

Subgroup Analysis: Elderly Participants

Participants aged 55 years and older, a demographic at heightened risk for oxidative damage and poor glycemic control, exhibited more pronounced improvements:

• HbA1c Reduction: Larger reductions in HbA1c were observed in elderly participants supplemented with GSH, Cohen's d values -0.41 (p < 0.001).
• Oxidative Stress Markers: The decrease in 8-OHdG was particularly significant in this subgroup, with Cohen's d values -1.5 (p < 0.001).
• Fasting Plasma Insulin (FPI): FPI levels improved in the intervention group, with Cohen's d values 0.56 (p < 0.01), suggesting improved pancreatic β-cell function.

Safety and Tolerability

• Adverse Events: No serious adverse events were reported during the study.
• Compliance: High compliance rates (>90%) were reported in the GSH group, ensuring reliability of the findings.

Mechanistic Insights

• Oxidative Stress Reduction:
• GSH supplementation restores redox balance by neutralizing reactive oxygen species (ROS) and reducing DNA and lipid damage.
• The increased GSH/GSSG ratio indicates enhanced antioxidant capacity and improved cellular resilience to oxidative insults.
• Improved Insulin Sensitivity:
• Lower oxidative stress may preserve pancreatic β-cell function, leading to better insulin secretion and glucose metabolism.
• Systemic Benefits:
• The observed reduction in HbA1c and glucose levels suggests that GSH supplementation supports both immediate and long-term glycemic control, which is crucial for preventing diabetes-related complications such as neuropathy, retinopathy, and cardiovascular diseases.

Clinical Implications

• Adjunct Therapy:
• The study highlights GSH as a promising adjunct to standard anti-diabetic therapy, particularly in managing oxidative stress, which is a critical but often overlooked component of diabetes care.
• Targeted Use in Elderly Populations:
• Elderly individuals, who are more vulnerable to oxidative damage and glycemic dysregulation, stand to benefit significantly from GSH supplementation.
• Potential Preventive Role:
• By reducing oxidative stress markers and improving glucose metabolism, GSH could potentially delay the onset of complications in T2DM patients.

Conclusion

This clinical trial provides robust evidence supporting the benefits of long-term GSH supplementation in improving oxidative stress and glycemic control in T2DM patients.

 Significant reductions in oxidative stress markers (e.g., 8-OHdG) and improvements in HbA1c levels, especially in the elderly participants, underscore the therapeutic potential of GSH.

Furthermore, its favorable safety profile makes it a viable candidate for integration into standard diabetes management protocols. Future research should explore long-term outcomes and synergistic effects with other therapeutic agents to maximize the benefits of GSH supplementation.

For full details, refer to the original article: https://pmc.ncbi.nlm.nih.gov/articles/PMC9137531/

You may explore our evercare GSH products here.